Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeoVax Labs (GOVX) Cash & Equivalents (2016 - 2025)

GeoVax Labs' Cash & Equivalents history spans 16 years, with the latest figure at $3.1 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $3.1 million for Q4 2025, down 43.97% from a year ago — trailing twelve months through Dec 2025 was $3.1 million (down 43.97% YoY), and the annual figure for FY2025 was $3.1 million, down 43.97%.
  • Cash & Equivalents for Q4 2025 was $3.1 million at GeoVax Labs, down from $5.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $34.7 million in Q3 2022 to a low of $768859.0 in Q1 2024.
  • The 5-year median for Cash & Equivalents is $12.1 million (2021), against an average of $13.8 million.
  • The sharpest move saw Cash & Equivalents soared 9296.81% in 2021, then tumbled 96.78% in 2024.
  • Year by year, Cash & Equivalents stood at $11.4 million in 2021, then soared by 141.71% to $27.6 million in 2022, then crashed by 76.63% to $6.5 million in 2023, then dropped by 14.66% to $5.5 million in 2024, then tumbled by 43.97% to $3.1 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $3.1 million, $5.0 million, and $3.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.